alpha-aminopyridine has been researched along with milrinone in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (96.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alousi, AA; Johnson, DC | 1 |
| Blinks, JR; Endoh, M; Taira, N; Yanagisawa, T | 1 |
| Meyer, W; Scholz, H | 1 |
| Braunwald, E; Colucci, WS; Wright, RF | 1 |
| Ahn, HS; Eardley, D; Prioli, N; Watkins, R | 1 |
| Hagen, A; Hagen, V; Heer, S; Mitzner, R; Niedrich, H | 1 |
| Johnston, GD | 1 |
| Janicki, JS; Maskin, CS; Weber, KT | 1 |
| Andersson, KE | 1 |
| Blas, SD; Cody, V; Davis, FB; Davis, PJ; Mylotte, KM; Schoenl, M | 1 |
| Komajda, M | 1 |
| LeJemtel, TH; Mancini, DM; Sonnenblick, EH | 1 |
| Beavo, JA; Chang, ML; Harrison, SA | 1 |
| Brutsaert, DL; Chalant, CH; Goenen, MJ; Sys, SU | 1 |
| Binah, O; Danilo, P; Rosen, M; Sodowick, B; Vulliemoz, Y | 1 |
| Kenyon, JL; Reeves, JP; Sutko, JL | 1 |
| Tommaso, CL | 1 |
| Beavo, JA; Cadd, GG; Gallis, B; Harrison, SA; Reifsnyder, DH | 1 |
| Ruggie, N | 1 |
| Baim, DS | 1 |
| Benotti, J; Benziger, DP; Chatterjee, K; Cody, R; Edelson, J; Hood, WB; Krebs, C; Luczkowec, C; Schwartz, R; Stroshane, R | 1 |
| Farah, AE | 1 |
| Hasegawa, GR | 1 |
| Beedle, EE; Elzey, TK; Hayes, JS; Jones, ND; Kauffman, RF; Robertson, DW; Swartzendruber, JK; Wilson, H | 1 |
| Goldfarb, JP; LeJemtel, TH; Manzione, NC; Maskin, CS; Sternlieb, I | 1 |
| Goldberg, LI | 1 |
| Carlier, J; D'Orio, V; el Allaf, D | 1 |
| Le Jemtel, TH; Maskin, CS; Sonnenblick, EH | 1 |
| Cai, R; Gao, Y; Han, Y; Hou, R; Li, X; Liu, H; Qi, R; Qi, Y; Zhang, X | 1 |
8 review(s) available for alpha-aminopyridine and milrinone
| Article | Year |
|---|---|
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Coenzymes; Enoximone; Heart; Heart Failure; Hemodynamics; Humans; Imidazoles; Injections, Intravenous; Milrinone; Nifedipine; Oxyfedrine; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Quinazolines; Ubiquinone | 1986 |
Effects of new inotropic agents on exercise performance.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Chronic Disease; Enoximone; Heart Failure; Humans; Imidazoles; Milrinone; Muscles; Oxygen; Oxygen Consumption; Physical Exertion; Pulmonary Wedge Pressure; Pyridones; Time Factors | 1986 |
Some new positive inotropic agents.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Dobutamine; Dopamine; Drug Tolerance; Enoximone; Heart Failure; Humans; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Practolol; Prenalterol; Pyridones | 1986 |
Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Calcium; Cardiac Output; Cardiotonic Agents; Cyclic AMP; Dose-Response Relationship, Drug; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Injections, Intravenous; Milrinone; Physical Exertion; Pyridones; Thrombocytopenia; Time Factors | 1986 |
Congestive heart failure.
Topics: Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Dobutamine; Dopamine; Heart Failure; Humans; Hydralazine; Milrinone; Nitrates; Nitroprusside; Prazosin; Pyridones; Sympathomimetics; Vasodilator Agents | 1986 |
Milrinone, a new agent for the treatment of congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 1986 |
Advances in cardiovascular pharmacology.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aminopyridines; Amrinone; Animals; Calcium Channel Blockers; Cardiovascular Agents; Dopamine; Heart Rate; Humans; Imidazoles; Milrinone; Myocardial Contraction; Pyridones; Receptors, Histamine; Vasodilator Agents | 1984 |
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Stimulation, Chemical; Time Factors; Xanthines | 1984 |
1 trial(s) available for alpha-aminopyridine and milrinone
| Article | Year |
|---|---|
Pharmacokinetics of the bipyridines amrinone and milrinone.
Topics: Administration, Oral; Aminopyridines; Amrinone; Clinical Trials as Topic; Half-Life; Heart Failure; Humans; Infusions, Parenteral; Kinetics; Male; Milrinone; Pyridones; Random Allocation; Time Factors | 1986 |
21 other study(ies) available for alpha-aminopyridine and milrinone
| Article | Year |
|---|---|
Pharmacology of the bipyridines: amrinone and milrinone.
Topics: Acetylcholine; Aminopyridines; Amrinone; Animals; Calcium; Carbachol; Cardiotonic Agents; Cats; Cyclic AMP; Dibutyryl Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Female; Guinea Pigs; Heart; Hemodynamics; Ion Channels; Male; Milrinone; Myocardial Contraction; Norepinephrine; Potassium; Pyridones; Receptors, Muscarinic; Sodium; Stimulation, Chemical; Time Factors; Verapamil | 1986 |
Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Aequorin; Aminopyridines; Amrinone; Animals; Calcium; Carbachol; Cardiotonic Agents; Colforsin; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; Enoximone; Female; Imidazoles; Male; Milrinone; Myocardial Contraction; Myocardium; Nifedipine; Nucleotides, Cyclic; Pyrazines; Pyridones; Quinolines; Time Factors | 1986 |
Phosphodiesterase-inhibiting properties of newer inotropic agents.
Topics: 1-Methyl-3-isobutylxanthine; Aminopyridines; Amrinone; Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Dose-Response Relationship, Drug; Guinea Pigs; Imidazoles; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Theophylline | 1986 |
Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Adenylyl Cyclases; Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Colforsin; Cyclic AMP; Enoximone; Guinea Pigs; Hydrolysis; Imidazoles; Isoenzymes; Milrinone; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridones | 1986 |
[Potential cardiotonic agents. 1. Synthesis and pharmacologic properties of 3-cyano-2-oxaalkylamino-5-(4-pyridinyl)pyridines].
Topics: Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Chemical Phenomena; Chemistry; Dogs; Guinea Pigs; Heart Rate; Hemodynamics; In Vitro Techniques; Male; Milrinone; Pyridines; Pyridones | 1989 |
Alternatives to the digitalis glycosides for heart failure.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyridones | 1985 |
Milrinone and thyroid hormone stimulate myocardial membrane Ca2+-ATPase activity and share structural homologies.
Topics: Aminopyridines; Amrinone; Animals; Calcimycin; Calcium-Transporting ATPases; Erythrocytes; Female; Male; Milrinone; Myocardium; Pyridones; Rabbits; Sarcolemma; Structure-Activity Relationship; Sulfonamides; Thyroxine; Triiodothyronine; Vanadium | 1985 |
[New cardiotonic agents].
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Colforsin; Deoxyepinephrine; Humans; Imidazoles; Levodopa; Milrinone; Practolol; Prenalterol; Propanolamines; Pyridones; Quinazolines; Xamoterol | 1985 |
New positive inotropic drugs for the treatment of congestive heart failure.
Topics: Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Dipeptides; Dobutamine; Enalapril; Heart Failure; Humans; Milrinone; Myocardial Contraction; Pyridones; Stimulation, Chemical; Vascular Resistance; Vasodilator Agents | 1985 |
Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
Topics: Aminopyridines; Amrinone; Animals; Antibodies, Monoclonal; Cardiotonic Agents; Cattle; Cyclic GMP; Enoximone; Imidazoles; Isoenzymes; Mice; Milrinone; Myocardium; Nucleotides, Cyclic; Phosphodiesterase Inhibitors; Pyridones; Rabbits | 1986 |
Inotropic effects of amrinone and milrinone on contraction and relaxation of isolated cardiac muscle.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Amrinone; Animals; Calcium; Cardiotonic Agents; Cats; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; Humans; Hypoxia; Milrinone; Myocardial Contraction; Oxygen; Pyridones; Ranidae; Rats; Sarcoplasmic Reticulum; Stimulation, Chemical; Temperature; Time Factors | 1986 |
The inotropic effects of amrinone and milrinone on neonatal and young canine cardiac muscle.
Topics: Age Factors; Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Cyclic AMP; Dogs; Heart; Lactates; Lactic Acid; Milrinone; Myocardial Contraction; Pyridones; Time Factors | 1986 |
Effects of amrinone and milrinone on calcium influx into the myocardium.
Topics: Aminopyridines; Amrinone; Animals; Calcium; Cattle; Cyclic AMP; Guinea Pigs; Milrinone; Myocardial Contraction; Myocardium; Purkinje Fibers; Pyridones; Rabbits; Rats; Sodium; Time Factors | 1986 |
Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Amrinone; Animals; Antibodies, Monoclonal; Cardiotonic Agents; Cattle; Chromatography, DEAE-Cellulose; Chromatography, High Pressure Liquid; Cyclic GMP; Enoximone; Imidazoles; Immune Sera; Kinetics; Mice; Mice, Inbred BALB C; Milrinone; Molecular Weight; Myocardium; Phosphodiesterase Inhibitors; Phosphorylation; Pyridones | 1986 |
Effects of amrinone on myocardial energetics in severe congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Coronary Circulation; Dogs; Enoximone; Heart; Heart Failure; Humans; Imidazoles; Isoproterenol; Milrinone; Myocardial Contraction; Myocardium; Oxygen Consumption; Phosphodiesterase Inhibitors; Pyridones | 1985 |
Historical perspectives on inotropic agents.
Topics: Alkaloids; Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Catecholamines; Cats; Digitalis; Digitalis Glycosides; Dogs; Europe; Glucagon; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Milrinone; Plants, Medicinal; Plants, Toxic; Pyridones; Ranidae; United States | 1986 |
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Crystallography; Dogs; Magnetic Resonance Spectroscopy; Milrinone; Models, Molecular; Myocardial Contraction; Pyridones; X-Ray Diffraction | 1986 |
New positive inotropic agents for congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Drug Evaluation; Heart Failure; Humans; Milrinone; Pyridones | 1986 |
The effects of two new inotropic agents on microsomal liver function in patients with congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Aminopyrine; Amrinone; Breath Tests; Cardiac Output; Cardiotonic Agents; Heart Failure; Humans; Liver; Liver Function Tests; Male; Microsomes, Liver; Middle Aged; Milrinone; Pyridones | 1986 |
Inotropic drugs for treatment of the failing heart.
Topics: Aminophylline; Aminopyridines; Amrinone; Cardiotonic Agents; Catecholamines; Digitalis Glycosides; Glucagon; Heart Failure; Hemodynamics; Humans; Milrinone; Myocardial Contraction; Pyridones; Receptors, Adrenergic, beta; Theophylline | 1984 |
Amlexanox exerts anti-inflammatory actions by targeting phosphodiesterase 4B in lipopolysaccharide-activated macrophages.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Inflammation; Interleukin-10; Lipopolysaccharides; Macrophage Activation; Macrophages; Male; Mice; Mice, Inbred ICR; Milrinone; NF-kappa B; Nitric Oxide; RAW 264.7 Cells; Signal Transduction; Spectrometry, Fluorescence; Transcription Factor AP-1; Tumor Necrosis Factor-alpha | 2020 |